Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second-Line Therapies

A Longitudinal Study

Sabrina Chiloiro; Chiara Bima; Tommaso Tartaglione; Antonella Giampietro; Marco Gessi; Liverana Lauretti; Carmelo Anile; Cesare Colosimo; Guido Rindi; Alfredo Pontecorvi; Laura De Marinis; Antonio Bianchi


J Clin Endocrinol Metab. 2019;104(11):5478-5482. 

In This Article

Material and Methods

The local ethics committee of Fondazione Policlinico Gemelli, Università Cattolica del Sacro Cuore approved the present study, and all the patients provided written informed consent. The inclusion criteria for the study population and control group are summarized in Table 1. The study population included six consecutive patients whose acromegaly was controlled through combination therapy with pasireotide and pegvisomant after the failure of other treatment lines. The control group included 49 consecutive patients. All 49 of these patients had disease resistance to conventional SSAs. Their acromegaly had been controlled by pegvisomant as monotherapy in five patients, combination therapy with conventional SSAs and pegvisomant in 24, and pasireotide as monotherapy in 20 patients.

A descriptive analysis was performed to determine the mean ± SD. The χ 2 test, or Fisher exact test, as necessary, and t test parametric test were used to compare the categorical and quantitative unpaired data. Statistical significance was assumed for P < 0.05. The data were analyzed using SPSS software, version 22 (IBM Corp.).